Abstract

Tirzepatide (Mounjaro) is a dual GLP‐1/GIP receptor agonist for the treatment of type 2 diabetes in adults. This article discusses its administration, clinical trial efficacy and adverse effects.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call